STOCK TITAN
  1. Home
  2. News
  3. BGNE

BeiGene Ltd - BGNE STOCK NEWS

IMPACT
SENTIMENT
BGNE : Nasdaq
BeiGene Announces Late-Breaking Data at ESMO Showing Tislelizumab plus Chemotherapy Significantly Improved Overall Survival at Final Analysis in First-Line Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
IMPACT
SENTIMENT
BGNE : Nasdaq
BeiGene Announces the Phase 3 RATIONALE 315 Trial Met Primary Endpoints of Major Pathological Response Rate and Event-Free Survival for Tislelizumab Plus Chemotherapy in Patients with Resectable Non-Small Cell Lung Cancer (NSCLC)
clinical trial
IMPACT
SENTIMENT
BGNE : Nasdaq
BeiGene Presentations at ESMO 2023 Demonstrate Robust Clinical Strategy for Tislelizumab as Monotherapy and in Combination with Pipeline Assets
IMPACT
SENTIMENT
BGNE : Nasdaq
BeiGene Receives Positive CHMP Opinion for BRUKINSA® (zanubrutinib) in Relapsed or Refractory Follicular Lymphoma
IMPACT
SENTIMENT
BGNE : Nasdaq
BeiGene Announces Positive Regulatory Updates in Europe and the U.S. After Recently Regaining Global Rights for TEVIMBRA®
IMPACT
SENTIMENT
BGNE : Nasdaq
BeiGene Strengthens Global Portfolio and Regains Full Rights from Novartis for Anti-PD-1 Antibody TEVIMBRA® (tislelizumab)
IMPACT
SENTIMENT
BGNE : Nasdaq
BeiGene to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
conferences
IMPACT
SENTIMENT
BGNE : Nasdaq
BeiGene Accelerates Global Momentum with Strong Second Quarter 2023 Financial Results
earnings
IMPACT
SENTIMENT
BGNE : Nasdaq
BeiGene Announces Positive CHMP Opinion for Tislelizumab as a Treatment for Advanced or Metastatic ESCC
IMPACT
SENTIMENT
BGNE : Nasdaq
BeiGene Announces FDA Acceptance of sNDA for Fifth BRUKINSA® Indication
clinical trial
Stock BGNE logo
BeiGene Ltd
Nasdaq:BGNE

BGNE Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Link

About BGNE

BeiGene is a biotechnology company that specializes in the development of drugs for cancer treatment. BeiGene has developed several pharmaceuticals, including tislelizumab, a checkpoint inhibitor, and zanubrutinib.